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Fungi are ubiquitous and we are constantly exposed to these eukaryotic microbes through acquisition 
from the environment, particularly the inhalation of fungal spores, or as part of the microbiome on 
our skin, mucosal surfaces and in our gastrointestinal tracts. Most fungi do not represent a serious 
threat to human health, but there are a few species which can cause life-threatening invasive diseases 
in immunocompetent individuals. Fortunately, the incidence of these infections is “relatively” rare. 
Fungi also cause superficial infections of the hair, skin, nails and mucosal membranes that are normally 
non-life threatening and easily treatable, but affect at least a quarter of the world’s population. 
Exposure to fungi is also thought to contribute significantly to allergies and asthma, which affects 
millions of people worldwide. Over the last few decades, however, there has been dramatic increase 
in the number of invasive infections caused by environmental and commensal fungi occurring in 
individuals whose immune function is compromised through modern immunosuppressive medical 
interventions and HIV/AIDS. In fact the numbers of deaths caused by these organisms is thought to 
exceed that of malaria and rival that of tuberculosis, and invasive fungal infections have some of the 
highest mortality rates of any infectious disease; exceeding 50% even with the best medical care. Our 
ability to tackle these unacceptably high rates of mortality stem from several factors, including 
difficulties in diagnosis and an insufficient antifungal armamentarium. Understanding the antifungal 
immune response is an area of considerable interest, given that defects in immunity underlie 
susceptibility to most invasive fungal diseases. In this issue, we focus on our current understanding of 
the impact of fungal interactions on the skin, mucosal surfaces, airways, gastrointestinal tract and 
during invasive disease. We also focus on the antifungal immune response and how immunity may be 
manipulated to combat fungal disease.  
 
Although a handful of human fungal pathogens are geographically restricted, the majority are 
environmentally widespread (e.g. Aspergillus, Cryptococcus and Mucormycete species) or reside as 
part of the normal human commensal microbiota (Candida and Malassezia species). Consequently, 
understanding the factors that govern the switch between tolerance/eradication or disease is a key 
challenge for fungal pathogenesis research. Hall and Noverr discuss the case of Candida albicans, a 
leading life-threatening fungal infection of humans worldwide. Unlike most fungal pathogens, C. 
albicans has evolved closely together with humans and consequently in most situations damage to 
the host represents an inappropriate host immune response. However, C. albicans also has a 
considerable range of weapons that it can deploy against the host, including the recently identified 
toxin Candidalysin covered elsewhere in this issue by Naglik and colleagues. Hall and Noverr discuss 
how these recent findings integrate into the “damage-response framework” first proposed by 
Casadevall and Pirofski [1] and propose a model of symbiosis that exists as a function of limited host 
damage. 
 
How fungi deal with nutrient stress is also key to their ability to survive in the host. Baltzer and Latge 
discuss the importance of metal homeostasis in Aspergillus fumigatus, a saprophytic organism that 
causes a whole range of human diseases from allergy to invasive infections. Being able to both 
assimilate metals required for growth, while simultaneously combat metal-mediated toxicity, requires 
a delicate balancing act involving carefully regulated processes that are integral to the virulence of the 
organism. A greater understanding of these complex mechanisms are likely to provide novel 
therapeutic approaches in the future. 
 
The other major fungal group found in close association with humans are the Malassezia species, 
which dominate the skin microbiota across most of the body. As Grice and Dawson describe, these 
species show considerable similarity to their plant-associated evolutionary cousins, including a 
remarkable panoply of lipid modification pathways, many of which impact on host immune signalling. 
Although most of us live comfortably together with our Malassezia residents, their ability to generate 
toxic by-products or to trigger inflammation occasionally leads to debilitating illness. Our investigation 
of this fungal group remains in its infancy, but the revolution in metagenomics studies is beginning to 
uncover their secrets.  
 
Similar approaches are also unveiling the extraordinary diversity of the gut microbiome. Although 
studies of gut-resident bacteria have been ongoing for many years, it is only relatively recently that 
researchers have begun to consider the fungal components of the microbiome. As discussed by 
Underhill and colleagues, this long-neglected set of organisms may have a major impact on human 
health. In particular, there is now growing evidence that the relative balance of different fungal species 
within the gut may be either protect against, or contribute towards, a range of inflammatory gut 
conditions. Ultimately, being able to modulate the balance of fungal species in the gut may thus offer 
the opportunity to profoundly alter our treatment of these disabling conditions. 
 
For fungal pathogens that are not resident commensals, the first point of entry to the human body is 
often the mucosal epithelium of the lung or gastrointestinal tract. Two reviews in this issue describe 
recent advances in understanding this host-pathogen interface. Klein and colleagues explore how the 
lung responds to the presence of fungal invaders and how, on occasion, this response to can wrong, 
leading to allergy and asthma. Similarly, Naglik and colleagues consider the molecular basis of 
epithelial immunity to fungi, with a particular focus on how the body discriminates between the 
presence of commensal, versus invasive, Candida species. Both of these reviews demonstrate the fine 
balance that the immune system must strike between preventing severe infection and yet not “over-
reacting” to common fungal antigens. 
 
Fungal infections with Mucormycete species are relatively infrequent. However, as Voelz and Ibrahim 
describe, these represent some of the deadliest fungal infections we know of, with mortality rates in 
excess of 90%. This largely represents a paucity of treatment options available for this fungal group, 
but a series of discoveries in recent years may provide a glimmer of hope on the horizon. In particular, 
exciting advances in understanding how these organisms attach to mammalian cells, scavenge 
essential micronutrients and disseminate through the host, may provide for new therapeutic angles 
in the near future. 
 
Although geographically restricted and consequently less numerous than opportunistic fungal disease, 
primary fungal infections are a major health concern in affected areas and an intriguing evolutionary 
enigma: what is it that allows these handful of species to cause life-threatening disease despite a 
robust human immune response? Rappeleye and colleagues consider these questions in the context 
of one major primary pathogen, Histoplasma capsulatum, and demonstrate that its ability to invade 
the host hinges on a remarkable capacity to hijack phagocytic cells of the host. To do so, Histoplasma 
relies on a unique and diverse armoury of virulence factors, which are only recently beginning to be 
deciphered.  
 
Considerable effort has focussed on those fungi which predominantly cause invasive disease in 
immunocompromised individuals. One of the best studied of such pathogens is Cryptococcus 
neoformans, which is responsible for more than 250 000 deaths in individuals suffering from 
HIV/AIDSi. Some of the more recent discoveries in this area have expanded our understanding of the 
early events post infection, as discussed by Ballou and Johnston in this issue, and have revealed how 
environmental factors both trigger and impact on, spore germination and viability once inhaled into 
the lung from the environment. The induction of cell division has been found to be critical for the 
regulated expression of key pathogenicity factors, including capsule size and structure, although the 
mechanisms integrating these processes remain unclear. Yet there remain important gaps in our 
knowledge, particularly regarding interactions with phagocytes, such as the pattern recognition 
receptors involved in yeast or spore uptake. In fact, even the mechanism(s) by which the fungus 
invades the central nervous system is still unclear. 
 
Pneumocystis jirovecii is another opportunistic fungal pathogen that kills at least as many 
immunocompromised people as C. neoformans, yet is far less well studied. The inability to culture this 
organism in vitro has significantly hindered progress in this field. The worldwide epidemiology of this 
organism is also not well described, because of diagnostic insufficiencies, but in low and middle-
income countries is thought to occur primarily in HIV+ individuals. In the western world, however, as 
discussed by Hoving and Kolls, the successful control of HIV has seen the prevalence of pneumocystis 
infections shift to the HIV-negative cases, including those suffering from haematological malignancies, 
on high dose corticosteroids and those with primary immune deficiencies affecting T-cell function.  
Macrophages are the key cell type responsible for killing the pathogen and T-cell function is also 
essential, but how T-cells actually mediate their protective activity is unclear.  
 
Patients with primary immunodeficiencies have provided significant insights into the mechanisms 
underlying antifungal immunity, an area of medical mycology which has advanced considerably over 
the last two decades. One particular group of patients, covered in the review from Li and colleagues, 
are those with genetic defects in IL-17 immunity that predisposes individuals to chronic 
mucocutaneous candidiasis (CMC). In fact, defects in CD4 T-cell function, as well as mutations in IL-17, 
its receptor and downstream signalling components are all associated with susceptibility to CMC. 
Mutations in CARD9, which functions as the major adaptor downstream of C-type lectin receptors, 
which induce Th17 and other key responses, leads to the most severe phenotypes, increasing 
susceptibility to CMC and subcutaneous infections but also to invasive infections by several fungal 
species.  
 
The central role of C-type type lectins in triggering key innate and adaptive antifungal immune 
responses is another area of intense interest. These receptors recognise the main carbohydrate 
constituents of the fungal cell wall, including mannan, β-glucan and chitin. In this issue, Shiokawa, 
Yamasaki and Saijo present an overview of the roles and functions of each of the major C-type lectin 
receptors involved in antifungal immunity (Dectin-1, Dectin-2, MINCLE and MCL), as well as describing 
some of the new insights into their roles in regulating the composition and immunological impact of 
the fungal constituents of microbiome. All these receptors utilise the Syk/CARD9 pathway to induce 
intracellular signalling, and while we do not yet fully understand how receptor specific responses are 
induced, several new components of this pathway have recently been identified, many with 
therapeutic potential. 
 
Understanding the antifungal immune response offers considerable potential for the development of 
new immunotherapies to treat patients suffering from invasive infections. In the final review of this 
issue, Scriven and colleagues, present an overview of the current state of the art in this field. They 
highlight some of the problems that are faced in reversing immune suppression, such as immune 
reconstitution inflammatory syndrome, as well as some of the promising adjunctive 
immunotherapeutic approaches that are being developed, such as administration of pro-
inflammatory cytokines. Other areas of current investigation include the transfusion of leukocytes, in 
the setting of neutropenia for example, or adoptive transfer of pathogen-specific or chimeric antigen 
receptor T cells. Treatment with antifungal antibodies and the development and antifungal vaccines 
also show promise, and are areas of active investigation. It is notable that there is not a single 
antifungal vaccine in current clinical use.  
[1] Casadevall A, Pirofski L-a: The damage-response framework of microbial 
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